← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Fairmount Funds Management LLC
10% Owner | Director
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001802528
Purchase history
- Companies traded
- 4
- Purchases · 12M
- 4
- Purchases · 24M
- 6
- Average purchase
- $15.3M
- Median purchase
- $15.3M
- Gross purchase value
- $91.6M
Companies: CRESCENT BIOPHARMA, INC. | Cogent Biosciences, Inc. | Viridian Therapeutics, Inc.\DE | Zenas BioPharma, Inc.
6 SEC accession(s) · 5 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-07-20 | CRESCENT BIOPHARMA, INC. | CBIO | Director | 10% Owner | $12.4M | Open filing |
| 2026-05-13 | Viridian Therapeutics, Inc.\DE | VRDN | Director | 10% Owner | $20.0M | Open filing |
| 2025-12-08 | CRESCENT BIOPHARMA, INC. | CBIO | Director | 10% Owner | $18.2M | Open filing |
| 2025-10-27 | Viridian Therapeutics, Inc.\DE | VRDN | Director | 10% Owner | $10.0M | Open filing |
| 2025-10-09 | Zenas BioPharma, Inc. | ZBIO | Director | $6.0M | Open filing |
| 2025-07-14 | Cogent Biosciences, Inc. | COGT | Director | $25.0M | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
No completed point-in-time price outcome is available yet.
Research patterns
- First purchase in 12M
- 2/4
- Large purchase ≥ $100k
- 6/6
- Cluster buying · 15D
- 5/6
- Buying the dip
- 0/—
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.